Delivery Order SPE2DB24D2101-SPE2DB25FKMRM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp for the supply of Lynparza 100 mg tablets (120 count) with a firm fixed price structure. This non-competitive delivery order, issued on July 21, 2025, is set to be completed by August 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Lynparza is a specialized oncology medication used in cancer treatment, reflecting DLA's role in...
- The Defense Logistics Agency awarded a $10,567.60 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of 120-count units of Lynparza 150 mg tablets, with completion scheduled for September 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Lynparza is a prescription oncology medication used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of LYNPARZA 100 mg tablets (120-count units) with a ceiling value of $10,519.62. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. LYNPARZA is an oncology pharmaceutical used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $31,558.86 to AmerisourceBergen Drug Corp for 120 tablets of LYNPARZA 100 mg on September 16, 2025, with completion scheduled for October 7, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. LYNPARZA is a prescription oncology medication used primarily in cancer treatment, reflecting the Defense...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120 count) valued at $10,567.60 under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of October 8, 2025. No set-aside designation was used for this procurement, indicating the award was made through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza (olaparib) 150 mg tablets in quantities of 120 units. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 4, 2025. The contract was awarded on July 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Lynparza...
- The Defense Logistics Agency awarded a $10,519.62 delivery order to AmerisourceBergen Drug Corp for Lynparza 100 mg tablets (120-count units) with a completion date of August 26, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement. The contract was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKMRMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp for the supply of Lynparza 100 mg tablets (120-count units) on July 23, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lynparza is a prescription oncology medication, and this delivery represents a routine pharmaceutical procurement supporting federal medical supply requirements. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle valued through December 2026. As a major pharmaceutical distributor and critical vendor for federal healthcare systems, AmerisourceBergen Drug Corp leverages this prime IDC to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military and veteran healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's consistent track record of competitively awarded contracts demonstrates its capability to fulfill diverse federal pharmaceutical procurement needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 7/23/25 |